Loma Linda University School of Medicine, Loma Linda, CA, USA.
Albany Medical College, Albany, NY, USA.
J Dermatolog Treat. 2022 Mar;33(2):622-625. doi: 10.1080/09546634.2020.1775774. Epub 2021 Jan 28.
In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis.
The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic.
Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized.
The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy.
Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis.
2019 年末，一种病毒性肺炎开始在全球范围内传播。这种病毒性疾病 COVID-19 现已正式成为大流行病，这引发了人们对银屑病患者接受系统性治疗的潜在风险的关注。
本综述旨在分析目前已知的 COVID-19 与系统性治疗安全性相关的信息，并为大流行期间银屑病的治疗提供指导。
对不同皮肤科监管机构针对 COVID-19 大流行期间使用系统性药物的指南进行了回顾和总结。
美国皮肤病学会、国家银屑病基金会和国际银屑病理事会一致建议，活动性 COVID-19 感染者应停止使用任何生物制剂治疗。
活动性 COVID-19 感染者应停止银屑病的系统性治疗。有风险因素的患者应根据具体情况讨论继续治疗的问题。
